HNRNPA2B1 and cancer: Kaplan–Meier and univariate Cox regression analysis for survival assessment showed that high expression of HNRNPA2B1 was a risk factor for LGG, GBMLGG, ACC, LIHC, KICH, LAML, CESC, LUAD, SARC, and PRAD patients and a protective factor for OV, and the prognostic impact of HNRNPA2B1 was consistent with expression in these cancers.